Compare OVV & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVV | RGEN |
|---|---|---|
| Founded | 2020 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 8.2B |
| IPO Year | N/A | N/A |
| Metric | OVV | RGEN |
|---|---|---|
| Price | $37.33 | $162.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 10 |
| Target Price | $49.50 | ★ $174.90 |
| AVG Volume (30 Days) | ★ 3.1M | 701.7K |
| Earning Date | 11-04-2025 | 10-28-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.90 | 0.03 |
| Revenue | ★ $8,794,000,000.00 | $707,890,000.00 |
| Revenue This Year | N/A | $17.84 |
| Revenue Next Year | $1.65 | $12.57 |
| P/E Ratio | ★ $41.52 | $5,259.20 |
| Revenue Growth | N/A | ★ 11.74 |
| 52 Week Low | $29.80 | $102.97 |
| 52 Week High | $46.35 | $182.52 |
| Indicator | OVV | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 39.49 | 54.15 |
| Support Level | $37.05 | $156.01 |
| Resistance Level | $38.86 | $165.02 |
| Average True Range (ATR) | 1.15 | 4.65 |
| MACD | -0.54 | -1.07 |
| Stochastic Oscillator | 4.64 | 43.33 |
Ovintiv Inc is a North American oil and natural gas exploration and production company that is focused on developing its multi-basin portfolio of high-quality assets located in the United States and Canada. Its operations also include the marketing of oil, NGLs and natural gas. The company has two operating segments: USA Operations, and Canadian Operations. The USA Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within the United States. The Canadian Operations include the exploration for, development of, and production and marketing of oil, NGLs, natural gas and other related activities within Canada.
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.